CareDx, Inc. reported significant financial growth in its latest quarterly filing, with total revenue reaching $131.9 million for the three months ended June 30, 2026, a 52% increase from $86.7 million in the same period last year. The company's testing services revenue surged by 61% to $99.9 million, driven by a 17% increase in testing volume, while patient and digital solutions revenue rose by 50% to $19.2 million. The company also recognized a gain of approximately $113 million from the sale of its lab products business, contributing to a net income of $110.6 million, compared to a net loss of $8.6 million in the prior year.
In comparison to the previous fiscal period, CareDx's financial performance showed marked improvement. For the six months ended June 30, 2026, total revenue increased by 46% to $249.6 million, with testing services revenue up 54% and patient and digital solutions revenue up 42%. The company’s operating expenses decreased significantly, primarily due to the gain on the sale of the lab products business, which offset other costs. The overall operating expenses for the first half of 2026 were $135.2 million, down from $195.9 million in the same period of 2025.
Strategically, CareDx completed the sale of its lab products business to Eurobio Scientific S.A. on June 30, 2026, which provided a substantial cash influx and allowed the company to focus on its core testing and digital solutions. Additionally, on July 1, 2026, CareDx acquired Naveris, Inc. for $161.8 million in cash, with potential additional payments based on revenue milestones. This acquisition is expected to enhance CareDx's position in precision medicine, particularly in transplant and oncology markets.
Operationally, CareDx reported a testing services volume of approximately 58,000 tests for the second quarter, reflecting a 17% year-over-year increase. The company also noted an average revenue per test of about $1,720, which includes $16 million in revenue recognized from prior periods. The company’s cash and cash equivalents stood at $373.6 million as of June 30, 2026, a significant increase from $65.4 million at the end of 2025, bolstered by the proceeds from the lab products business sale.
Looking ahead, CareDx anticipates continued growth driven by its core testing services and digital solutions. The company plans to invest in research and development to expand its product offerings and improve patient outcomes. Management expressed confidence that the existing cash balance and expected cash flows from operations will be sufficient to meet anticipated cash requirements for the next 12 months. The company remains focused on enhancing its market position through strategic acquisitions and product innovations in the precision medicine space.
About CareDx, Inc.
CareDx is a precision medicine company specializing in the discovery, development, and commercialization of high-value diagnostic solutions for transplant patients. Its core offerings include molecular diagnostic tests, digital patient management tools, and lab products that improve transplant outcomes. Serving transplant centers and healthcare providers primarily in the U.S. and Europe, CareDx leverages genomic technologies and data-driven solutions to enhance organ rejection detection, patient monitoring, and operational efficiency.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov